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INTRODUCTION
IN THE DECADE SINCE THE VITAMIN D RECEPTOR (VDR) wascloned(1) and recognized as a member of the super-
family of nuclear receptors that regulate gene expression
in a ligand-dependent manner,(2,3) the central role of
VDR in the biology of vitamin D action has been illumi-
nated and is being defined at the molecular level. Fol-
lowing renal production as the hormonal metabolite of
vitamin D, 1a,25-dihydroxyvitamin D3 (1,25(OH)2D3) func-
tions as the ligand for VDR, with the hormone–receptor
complex inducing calcemic and phosphatemic effects that re-
sult in normal bone mineralization and remodeling. VDR not
only mediates the action of 1,25(OH)2D3 in calcium/phos-
phate translocating tissues, primarily intestine, but also elicits
a myriad of apparent bioactivities in other major cell systems
in the organism, including immune, neural, epithelial, and
endocrine. The scope of this review will be limited to high-
lighting the actions of 1,25(OH)2D3 mediated by nuclear
VDR and discussing new developments in the structure/func-
tion analysis of the receptor, including the phenotype of VDR
knockout mice and the biochemical classification of patients
with point mutations in the receptor. These new advances,
along with other recent research, will be interpreted to update
our understanding of the molecular role of VDR, ranging
from characterization of its natural gene and clinically signif-
icant polymorphisms, through its DNA contact sites and pro-
tein partners, to novel ligand analogs that hold the promise of
influencing VDR conformation in a therapeutically beneficial
fashion.
VDR BIOLOGY
Pathophysiology of the vitamin D endocrine system
and bone mineral metabolism
The traditional action of vitamin D, via its 1,25(OH)2D3
hormonal metabolite, is to effect calcium and phosphate
homeostasis to ensure the deposition of bone mineral (sum-
marized in Fig. 1A). 1,25(OH)2D3 stimulates intestinal cal-
cium and phosphate absorption, bone calcium and phos-
phate resorption, and renal calcium and phosphate
reabsorption, thus increasing the blood Ca•PO4 ion prod-
uct. Failure to achieve normal bone mineral accretion by
these mechanisms leads to rachitic syndromes. Nutritional
rickets, caused by the simultaneous deprivation of sunlight
exposure(4) and dietary vitamin D, was ameliorated in clas-
sic experiments by administration of this fat soluble vitamin
(reviewed in Ref. 5). Subsequently, it was recognized that
the pathways comprising the metabolic activation of the
vitamin to its hormonal form and consequent functions of
the hormone in target tissues (Fig. 1) present additional
steps where defects directly elicit vitamin D–resistant ra-
chitic syndromes. Two such disorders involve the inade-
quate bioactivation of 25-hydroxyvitamin D3 (25(OH)D3), a
constitutively produced intermediary metabolite, to 1,25-
(OH)2D3. This step is catalyzed by the 1a-OHase enzyme in
kidney (Fig. 1A). Chronic renal failure results in renal
rickets and secondary hyperparathyroidism when compro-
mised renal mass reduces 1a-OHase activity,(6) whereas
pseudo–vitamin D–deficiency rickets (PDDR) involves a
specific hereditary defect in the gene coding for the 1a-
OHase enzyme.(7) The latter conclusion has been verified
by the recent cloning of cDNAs for the rat(8) and mouse(9)
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FIG. 1. Calcemic and phosphatemic biological actions of vitamin D in mammals. (A) Effects of vitamin D and its
metabolites to ensure skeletal integrity, especially when calcium is limiting. (Central open box) Vitamin D3, obtained from
diet or derived from sunlight-initiated photobiogenesis in skin, is converted via two hydroxylation reactions to the
1,25(OH)2D3 hormonal form that circulates in blood. The final step in bioactivation of vitamin to hormone is catalyzed by
the renal 1a-OHase when stimulated by PTH under conditions of low calcium. (Lower portion) Integrated actions of the
1,25(OH)2D3 metabolite, via binding to the intracellular VDR, to control calcium homeostasis in bone, intestine, kidney,
and parathyroid as explained in the text. (Top left) Action of 1,25(OH)2D3–VDR in skin cell differentiation. (Top center)
Conversion of 1,25(OH)2D3 or the preceding 25(OH)D3 metabolite to 24-hydroxylated forms in response to
1,25(OH)2D3–VDR induction of the 24-OHase gene. This conversion serves to initiate catabolism of the vitamin D
molecule, but may also produce 24-hydroxylated metabolites with novel hormonal activity with respect to chondrocyte
differentiation and bone mineralization (see text). (B) The vitamin D bioactivation-phosphate homeostatic loop: proposed
novel roles for phosphatonin, the PEX gene product, and NPT2. (Left and lower portion) Under normal physiologic
conditions, low PO4 enhances the synthesis of 1,25(OH)2D3, which then acts through VDR to effect phosphate reclamation
by suppressing PTH as well as inducing NPT2 and PEX gene expression. NPT2 acts directly to reabsorb PO4, while the
PEX enzyme eliminates phosphatonin. (Top right) Tumor-induced osteomalacia and XLH each elicit increased phospha-
tonin, an uncharacterized phosphaturic hormone that is postulated to inhibit both NPT2 and the 1a-OHase, to cause
severe phosphate wasting.
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1a-OHase P450 and the pinpointing of the human 1a-
OHase gene to a chromosomal locus coincident with
PDDR.(8) Interestingly, the 1a-OHase/PDDR locus maps
rather closely to the VDR gene on chromosome 12 in the
12q13–14 region,(7) a proximity that may be relevant to the
evolution and control of the vitamin D ligand–receptor system.
Hypocalcemic 1,25(OH)2D3 resistance
Clinical and molecular genetic data from the last decade
have provided unequivocal evidence for the obligatory role
of VDR in mediating the action of vitamin D. Familial
target tissue insensitivity to 1,25(OH)2D3, known as hered-
itary hypocalcemic vitamin D–resistant rickets (HVDRR),
is an autosomal recessive disorder resulting in a phenotype
characterized by severe bowing of the lower extremities,
short stature, and often alopecia.(10) In virtually all cases,
the cause of this syndrome has been shown to be a defect in
the gene encoding human VDR (hVDR) (reviewed in Refs.
10–13), although potential exceptions have been de-
scribed.(14,15) The fact that the phenotype of HVDRR pa-
tients, excluding alopecia, mimics classic nutritional rickets
indicates that 1,25(OH)2D3-liganded VDR not only exe-
cutes all of the bone mineral homeostatic actions of
1,25(OH)2D3 but suggests that VDR itself also participates
in the normal hair growth cycle in skin.
Generation of VDR null mice
Recently, VDR knockout mice have been created by two
groups,(16,17) revealing apparently normal heterozygotes
but homozygotes that display a phenotype very similar to
HVDRR, including the progressive development of alope-
cia over 4–7 weeks of age. At various intervals after birth
(differing somewhat between the two studies), VDR null
mice acquired low bone mass, hypocalcemia, hypophos-
phatemia, hyperparathyroidism, and 10-fold elevated 1,25-
(OH)2D3, coincident with extremely low 24,25(OH)2D3.
Affected homozygotes died within 15 weeks(16) or exhibited
near normal survival rates for up to 6 months.(17) The
differing survival times may be related to diet or environ-
mental variations, since ablation of exon II/first zinc fin-
ger(16) or exon III/second zinc finger(17) should produce
equivalent functional consequences of VDR gene knock-
out. Despite a lack of VDR throughout early development,
VDR null mice are born phenotypically normal, exhibiting
symptoms of rickets/osteomalacia and secondary hyper-
parathyroidism primarily after weaning.(16) This observa-
tion suggests that the vitamin D endocrine system is prin-
cipally required for maintaining bone mineral homeostasis
when the organism is deprived of a consistent and plentiful
supply of calcium, such as occurs after weaning in mam-
mals, after hatching in birds, or after leaving the aqueous
environment in the case of amphibians.(18)
In addition to the data reported in their abstract, Demay
and coworkers(19) also presented preliminary results de-
scribing the prevention of many, but not all, of the pheno-
typic effects of VDR knockout by means of a “rescue diet,”
consisting of high levels of lactose, calcium, and phosphate.
By manipulating blood calcium and phosphate levels in this
manner, parathyroid hormone (PTH) was normalized and
bone mineralization was greatly improved in the VDR
knockout animals, to a degree that the histology of the
growth plate was indistinguishable from that of normal
littermates. However, alopecia and skin abnormalities, such
as dermal cysts, persisted in the VDR null mice on the
rescue diet, intimating that VDR plays an indispensable
role in hair and skin development independent of bone
mineral homeostasis. That normalizing circulating mineral
concentrations via dietary intervention in VDR knockout
mice prevents the rachitic phenotype is consistent with
results in HVDRR patients whose bone abnormalities are
resolved by frequent therapy with overnight intravenous
calcium infusions.(20,21)
Thus, the generation of VDR null mice and the reversal
of their bone abnormalities by diet dramatizes the concept
that the major physiologic effect of 1,25(OH)2D3 is on
intestinal absorption of calcium and phosphate, although
certain calcium regulating end-points such as depressed
renal calbindin-D9k mRNA expression in kidney are not
corrected when VDR null mice are maintained on the
rescue diet (M. Demay et al., unpublished results). More-
over, in another preliminary study, Kato and colleagues(22)
found that, when utilizing the coculture system of Suda and
coworkers,(23) osteoblasts/stromal cells from VDR knock-
out mice will not support 1,25(OH)2D3-induced osteoclas-
togenesis of normal spleen cells, whereas the reverse exper-
iment (normal osteoblasts/stromal cells and VDR null
mouse spleen cells) results in the production of osteoclasts
upon exposure of the coculture to 1,25(OH)2D3. Therefore,
as depicted in Fig. 1(A), VDR appears to be essential for
1,25(OH)2D3 to elicit a paracrine signal from osteoblasts,
which in turn facilitates osteoclast differentiation, at least in
vitro. However, the fact that VDR null mice curiously
possess normal, or even increased numbers of oste-
oclasts(16) suggests that other osteoclast-activating factors,
such as PTH or interleukin-1 (IL-1), can still support osteo-
clastogenesis in the absence of functional VDR.
The participation of VDR in feedback control of the
vitamin D endocrine system
Superimposed upon its pivotal role in controlling bone
mineral transport and differentiation in hair follicles, an-
other function of the 1,25(OH)2D3–VDR complex is to
govern the level of the renal 1,25(OH)2D3 hormone by
feedback regulation of its biosynthesis and by induction of
a key catabolic enzyme. 1,25(OH)2D3 appears to effect a
short feedback loop (Fig. 1A) to repress the 1a-OHase
enzyme,(24) and is also a potent suppressor of the synthesis
and secretion of PTH,(25) the primary tropic hormone stim-
ulating the 1a-OHase (Fig. 1).(26) The mechanism whereby
1,25(OH)2D3 curtails PTH production involves a VDR-
mediated silencing of PTH gene transcription.(27–29) Based
upon preliminary data from dietarily rescued VDR null
mice, excess calcium is able to adequately control PTH
secretion and parathyroid cell growth, suggesting that the
role of 1,25(OH)2D3 in these processes is cooperative with
physiologic calcium levels but can be overridden in situa-
tions of calcium abundance.
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Catabolism of 1,25(OH)2D3 and generation of 24-
hydroxylated vitamin D metabolites
Turnover of 1,25(OH)2D3 is accomplished via several
catabolic routes,(30,31) with 24-hydroxylation initiating the
apparent primary pathway for elimination of vitamin D
metabolites. The 24-OHase enzyme is markedly enhanced
by 1,25(OH)2D3 through a VDR-dependent mechanism
(Fig. 1A), a phenomenon predominating in kidney but also
occurring in all 1,25(OH)2D3 target cells.
(32,33) The depen-
dency of 24-OHase activity on VDR action is emphasized
by the extremely low levels of 24-hydroxylated metabolites
found in VDR null mice, as discussed above.(16) Both the 25-
(OH)D3 precursor and the 1,25(OH)2D3 hormone serve as
effective substrates for the 24-OHase enzyme, rendering
the latter capable of catalyzing a potent attenuation of
active vitamin D metabolite concentrations. In fact, ho-
mozygous 24-OHase null mice(34) display reduced 1,25-
(OH)2D3 clearance, with the F1 progeny exhibiting signs of
vitamin D intoxication, such as calcified kidneys. Interest-
ingly, the F1 progeny also have defective intramembranous
ossification. The failure of bones such as the calvaria and
mandible to calcify in this situation could be a developmen-
tal consequence of excess 1,25(OH)2D3. Another possibility
is that a 24-hydroxylated D-metabolite(s) is required for
some aspect of cartilage or bone formation (Fig. 1A),(35–38)
perhaps via pharmacokinetic interactions with 1,25-
(OH)2D3 or through an uncharacterized novel receptor for
the 24-hydroxylated metabolite.
The role of 1,25(OH)2D3–VDR in
phosphate homeostasis
Other than negative feedback on PTH synthesis and
secretion(27,39) to suppress this phosphaturic hormone, how
does the 1,25(OH)2D3–VDR complex influence phosphate
metabolism to maintain the Ca•PO4 ion product? One
mechanism seems to be the primary induction of phosphate
translocating proteins in kidney and perhaps intestine
(Fig. 1). An example is the renal sodium–phosphate co-
transporter-2 (NPT2) (Fig. 1B),(40,41) a likely 1,25(OH)2D3-
induced protein because its gene contains a vitamin D
responsive element (VDRE) in the promoter region (see
below). It is also well established that hypophosphatemia
stimulates the 1a-OHase (Fig. 1B) to elevate circulating
1,25(OH)2D3 levels.
(26) However, circulating 1,25(OH)2D3
is inappropriately low for the prevailing phosphate concen-
trations in patients with X-linked hypophosphatemic rickets
(XLH),(42) a dominant familial disorder of renal phosphate
wasting. Importantly, such patients can be cured with a
therapeutic combination of oral phosphate and 1,25-
(OH)2D3.
(43) The defective gene responsible for XLH has
been identified as PEX, or phosphate-regulating gene with
homologies to endopeptidases located on the X-chromo-
some.(44) Further, there exists a significant number of cases
of tumor-induced osteomalacia, an acquired disorder that
closely resembles the phosphate wasting of XLH and is
characterized by low circulating 1,25(OH)2D3.
(45) Finally,
renal cross-transplantation(46) and parabiosis(47) studies in
normal and genetically hypophosphatemic mice demon-
strate that a novel uncharacterized phosphaturic hormone
is present in the circulation. Taken together, these obser-
vations argue strongly that the XLH and tumor-induced
osteomalacia syndromes are both caused by excess amounts
of this novel humoral factor, which is distinct from PTH and
has been named phosphatonin (Fig. 1B).(48,49) Like PTH,
phosphatonin is presumably a potent inactivator of NPT2
(Fig. 1B), but in contrast to PTH, this newly recognized
factor apparently also inhibits the 1a-OHase, thus suppress-
ing 1,25(OH)2D3. As depicted in Fig. 1(B), the normal role
of the PEX gene product is postulated to be the proteolytic
inactivation of this phosphaturic principle, such that inac-
tivating PEX mutations in XLH elicit the appearance of
abnormally high circulating levels of phosphatonin.(44) In
the case of tumor-induced osteomalacia, the tumor appears
to produce phosphatonin ectopically. Thus, as illustrated in
Fig. 1(B), the PEX/phosphatonin system could participate
in a novel regulatory loop for maintaining normal phos-
phate homeostasis, which becomes deranged in XLH, or
when tumors directly secrete phosphatonin.
Another role of 1,25(OH)2D3/VDR in phosphate control
is postulated to be the induction of PEX gene expression
(Fig. 1B), thus creating an additional strategy for protection
by 1,25(OH)2D3 against hypophosphatemia. Indeed, the
PEX gene appears to possess a VDRE based upon South-
western analysis of the relevant yeast artificial chromo-
some.(50) The present hypothesis is that a low phosphate
level triggers an increase in circulating 1,25(OH)2D3, which
in turn augments the PEX gene product to destroy phos-
phatonin, constituting a novel phosphate homeostatic loop
that is overwhelmed when high levels of phosphatonin di-
minish 1,25(OH)2D3 synthesis and inhibit NPT2. This con-
cept is consistent with the relatively depressed 1,25-
(OH)2D3 levels observed either in patients with tumor-
induced osteomalacia or in kindreds with XLH caused by
inactivating PEX mutations. Given the present indications
that phosphatonin represents a pathophysiologically rele-
vant phosphaturic hormone that regulates vitamin D bio-
activation, its characterization at the chemical level is ea-
gerly anticipated.
Neoclassical 1,25(OH)2D3/VDR actions
As summarized in Table 1, the potential actions of
1,25(OH)2D3 via its nuclear VDR extend far beyond the
bone mineral homeostasis realm pictured in Fig. 1. The
following three independent methodologies have been em-
ployed to provide evidence that 1,25(OH)2D3 functions in a
diverse array of cells: autoradiographic localization of the
ligand following administration to vitamin D–deficient an-
imals, immunohistochemical detection of VDR in the nu-
cleus of target cells, and responsiveness of specific cell types
in culture to 1,25(OH)2D3 and its active analogs. In many
cases, these data are coupled to biological responses or to
loss of function in VDR null mice, in vivo, for instance in
the maintenance of insulin secretion by 1,25(OH)2D3,
(51)
the uterine hypoplasia reported in VDR knockout female
mice apparently caused by suboptimal ovarian estrogen
production,(16) and the exploitation of the prodifferentia-
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tion/antiproliferative actions of 1,25(OH)2D3 in the treat-
ment of psoriasis.(52)
One major neoclassical target for 1,25(OH)2D3 is the
immune system (reviewed in Ref. 53), with the suppression
of IL-1 to IL-6 and interferon-g constituting prominent in
vitro 1,25(OH)2D3 effects mediated by VDR (Table 1).
Moreover, in vivo immunomodulatory actions of the hor-
mone also have been documented (reviewed in Ref. 54),
such as reduced macrophage and lymphocyte function in
vitamin D–deficient rats.(55) 1,25(OH)2D3 functions as a
general suppressor of the immune system, especially of
T-helper cells (subset type 1), suggesting that analogs of
vitamin D might be useful therapeutic agents in procedures
such as organ transplants(56) or in the treatment of autoim-
mune disorders.(57) In addition, 1,25(OH)2D3 is thought to
play an important role in the differentiation of cells in the
hematopoietic lineage. Several illustrations of this action
have been reported, including differentiation of a human
promyelocytic leukemia cell line (HL-60) into macrophage-
like cells,(58,59) and the development of osteoclasts in bone
from colony forming unit–granulocyte/macrophage precur-
sors (see Ref. 53 and references therein). Many of these
effects of 1,25(OH)2D3–VDR, although of potential thera-
peutic significance, may be biologically redundant with
other immune modulators, perhaps offering survival advan-
tages. The tentative conclusion of redundant immunoregu-
lation is based upon the normal immune profile of VDR
null mice at 7 weeks of age,(16) but it is reasonable to
hypothesize that the potential immunomodulatory power of
1,25(OH)2D3–VDR could become more significant during
pathophysiological stress situations or under conditions of
senescence.
Other apparent sites of action for 1,25(OH)2D3 and
VDR include the central nervous system (CNS) (Table 1),
where one of the outcomes is immunosuppression. For
example, 1,25(OH)2D3 treatment elicits a partial improve-
ment of symptoms in rodents with developing experimental
allergic encephalomyelitis.(60,61) Moreover, 1,25(OH)2D3
also has been shown to induce expression of the following
neurotrophic hormones or their mRNAs: glial cell-derived
neurotrophic factor (a protein that may be important in
protecting certain types of neural tissue from degenerative
processes),(62) leukemia inhibitory factor (a widely distrib-
uted protein in the brain with neurotrophic activity),(63)
neurotrophin-3 mRNA (in primary astrocytes),(64) and
nerve growth factor (both in primary newborn astrocytes(65)
and in the hippocampus and cortex of the adult rat(66)).
Furthermore, the activity of cholinergic acetyltransferase is




(67) In some neurons, analogous to
the antiapoptotic effect of calbindin-D28k in lympho-
cytes,(68) the induction of calbindins by 1,25(OH)2D3 may
protect against cell death in the face of repetitive calcium
transients,(69) and in fact the expression of calbindin-D28k
mRNA is decreased in the hippocampus of Alzheimer’s
patients as assessed by in situ hybridization.(70,71) Taken
together, these observations not only imply a modulatory
role for VDR in neural cell growth and differentiation but
also intimate a possible role for 1,25(OH)2D3 in therapeutic
intervention for neurodegenerative disorders.
Similarly, 1,25(OH)2D3 appears to affect dramatically the
maturation and functions of certain normal and neoplastic
epithelial cells (Table 1). As discussed above, VDR plays a
TABLE 1. NEOCLASSICAL 1,25(OH)2D3 TARGET SITES
Classification Target tissue or cell* Specific effects†
Immune system monocytes/macrophages(53) and T-
lymphocytes (helper type 1)(53,57)




dorsal root ganglia,(204) glial cells, and
hippocampus(70,107)
production of NGF,(65,66,205) neurotrophin-3,(64)
and leukemia inhibitory factor(63)
Epithelium epidermal skin/keratinocyte(206) differentiation(17,211)
hair follicle(207) differentiation(16,17,212)
female reproductive tract(208) uterine development(16)
mammary(108) 2 cell growth(213)
prostate(209) 2 cell growth(173)
colon(210) 2 cell growth(170,214)
lung(108) surfactant(215)
Endocrine system thyrotrope(216) TRH receptor(218)
thyroid(108) 2 TSH action(219)
pancreatic b-cell(217) insulin secretion(51)
ovary(208) folliculogenesis(16) and 2 cell growth(220)
Muscle heart(221) 2 ANP(222,223)
Adipose adipocyte(224) lipoprotein lipase(225)
Many systems diverse cells and cancer cell lines(173,226,227) 2 cell growth (c-fos(179); 2 c-myc(58,157)),
differentiation (p21(228); p27(229); Mad-1(230))
and apoptosis(213)(2 Bcl-2(231,232))
*Detected by autoradiographic ligand localization in the nucleus, VDR immunocytochemistry, or responsiveness of cultured cells.
†Effects of 1,25(OH)2D3 are positive unless otherwise noted and are selected examples rather than a comprehensive list.
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key role in the hair growth cycle, an action related to the
ability of 1,25(OH)2D3 to stimulate the differentiation of
keratinocytes (Table 1). Also, the proliferation of a number
of epithelially derived cancer cells (e.g., mammary, pros-
tate, and colon) is inhibited in culture by 1,25(OH)2D3, with
some cells being directed toward a more differentiated
phenotype. This effect in neoplastic cells may be related to
the reported ability of liganded VDR to arrest cells at the
G1 stage by influencing cell cycle regulatory proteins, such
as p21 and p27, to control cell growth transcription factors
such as c-myc and c-fos, or to elicit apoptosis by down-
regulating Bcl-2 (Table 1 and references therein). There-
fore, the 1,25(OH)2D3 hormone seems to resemble its nu-
tritionally derived, lipophilic ligand cousins, vitamin A and
thyroid hormone, in possessing the ability to influence the
program of cell development as well as to evoke classic
metabolic and growth regulatory effects. 1,25(OH)2D3 also
reportedly affects several major endocrine processes, such
as TRH/TSH action and pancreatic insulin secretion
(Table 1). However, only further investigations of VDR null
mice and other transgenic strategies, such as tissue-specific
expression of a dominant negative VDR, will allow us to
sort out which of the putative neoclassical effects of
1,25(OH)2D3 mediated by VDR are biologically relevant.
At this early juncture, of those sites enumerated in Table 1,
only the skin/hair growth cycle and ovarian/uterine systems
appear to be markedly affected in the VDR null mouse.
However, the limited phenotype of VDR knockout mice
does not preclude 1,25(OH)2D3 and its analogs from being
valuable as biological response modifiers useful in the treat-
ment of hyperproliferative disorders, autoimmunity, and
CNS deterioration, as well as traditional maladies of cal-
cium and phosphorus metabolism such as renal osteodys-
trophy, hypoparathyroidism, and osteoporosis.
FIG. 2. Schematic view of genomic and deduced amino acid sequences for hVDR, displaying known natural variations.
(A) The hVDR chromosomal gene, containing a total of 11 exons, three of which (IA, IB, and IC) encode 59 UTR region
and are variably present in VDR transcripts.(72) Several polymorphic variants, including a FokI site in exon II, and a cluster
of linked sites near or in exon IX, are discussed in the text. (B) Schematized linear amino acid sequence of hVDR,
highlighting functional domains as currently understood from mutagenesis analysis. Q signifies a cluster of five basic amino
acids in the intervening sequence between the two zinc fingers. Two reported sites of modulatory serine phosphorylation
at serine-51 and serine-208 are indicated by S51 and S208, respectively. Known natural point mutations in human patients
with the HVDRR syndrome are indicated by single-letter abbreviations (e.g., G33D is a glycine to aspartate substitution
at position 33). X refers to a premature stop codon, while f indicates a frame-shift mutation, leading to premature
termination. Point mutants from positions 33–80 are defective in DNA binding, and all X and f mutants can neither bind
hormone nor heterodimerize with RXR. Other point mutations in the C-terminal half of the receptor (from positions
259–391) display defects in either hormone-binding or heterodimer formation with RXR (or both) as discussed in the text.
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STRUCTURE/FUNCTION OF THE VDR
GENE AND PROTEIN
hVDR chromosomal gene
The recently characterized gene encoding hVDR
(Fig. 2A),(72) previously localized to chromosome 12,(73) is
similar to other nuclear receptor genes(74) in that each of
the two zinc fingers is encoded by separate exons (II and
III), and the 59 end of the gene exhibits some complexity in
the form of alternate splice and/or translation start sites.
For hVDR, alternate splicing of three exons (IA–IC) en-
coding portions of the 59 untranslated region generates at
least three mRNA variants,(72) while the presence of a
polymorphic sequence in exon II determines the presence
or absence of an alternative translation start site (see dis-
cussion of FokI polymorphism below).(72) A unique feature
of the hVDR gene is the presence of an additional exon (V)
that is not found in other nuclear receptor genes
(Fig. 2A)(72); it resides near the center of the gene and
encodes residues 155–194 in hVDR. This region of the
VDR protein is more expansive than the corresponding
segment in other nuclear receptors, suggesting that the
VDR may have acquired a novel exon of unknown function
as it diverged evolutionarily from other nuclear receptor
genes.(72)
hVDR polymorphisms
One of the most intriguing, yet controversial, areas of
bone-related genetic research in the past few years has been
the discovery of common polymorphisms in the hVDR gene
and their potential relationship to bone mineral density
(BMD) and the pathophysiology of osteoporosis, hyper-
parathyroidism, and cancers of the breast and prostate.
Morrison, Eisman, and colleagues(75) first reported that
VDR alleles could predict BMD, contending that the oc-
currence of a BsmI restriction site (Fig. 2A, denoted b) in
the intron separating exons VIII and IX of the gene
(Fig. 2A) is associated with enhanced lumbar spine BMD.
Conversely, the absence of the BsmI site (denoted B) in
VDR was correlated with low BMD. In a population of
Australian twins of Irish ancestry, Morrison et al.(75) con-
cluded that the VDR genotype (b vs. B) accounted for up to
75% of the genetic component of BMD, although a correc-
tion/partial retraction of this report appeared recently.(76)
Numerous subsequent studies with other population sam-
ples have found more modest,(77,78) little if any,(79–82) and
even conflicting associations(83) of the B versus b alleles
with BMD. A meta-analytic approach(84) that incorporated
the results of 16 VDR polymorphic studies revealed a 1.5–
2.5% decrease in BMD associated with BB (versus bb)
homozygotes, far less dramatic than the 12% effect origi-
nally proposed.(75) Additional studies have also suggested a
trend toward lower bone mass with the B allele,(85–88) but it
has become clear that other confounding factors, such as
age, estrogen status, ethnicity, and calcium intake, must be
accounted for to reveal the true impact, if any, of this VDR
polymorphism on BMD.
Further evaluation of the VDR gene has revealed a
cluster of linked polymorphisms in the 39 portion of the
VDR gene (Fig. 2A),(89) including the aforementioned
BsmI site, a nearby ApaI site (in the same intron), and a
silent mutation within codon 352 of the ninth exon that
alters a TaqI site. These VDR polymorphisms have been
linked not only to variations in bone-specific parameters
but also to a higher occurrence of sporadic primary hyper-
parathyroidism in patients with the b allele,(90) as well as to
prostate cancer, which possesses a particularly strong asso-
ciation with the T allele (lack of the TaqI site).(91) However,
given that none of these polymorphisms change the en-
coded VDR protein in any way, the explanation for these
findings has been unclear. Recently, an additional genetic
variation in the hVDR gene was found in the form of a
microsatellite poly(A) repeat in the 39 UTR, approximately
1 kb upstream of the poly(A) tail (Fig. 2A). Multiple ($12)
allelic variants of this microsatellite were detected and clas-
sified into two groupings, long (L) and short (S), based
upon the length of the repeat.(92,93) The L grouping (linked
to T; see Fig. 2A) exhibits a strong association with prostate
cancer incidence(93) but displays a contrasting protective
effect against breast cancer.(94) It is still not established
whether this poly(A) microsatellite is the functionally rele-
vant locus, although by analogy to short tandem repeats in
other genes(95) the length of the repeat may affect a crucial
parameter, such as mRNA stability. Alternatively, the
poly(A) microsatellite may be tightly linked to yet another
site which is the true functional locus. Regardless of which
scenario is correct, a complicating factor in interpreting
earlier findings using the BsmI, TaqI, or ApaI polymorphic
restriction sites is that the linkage is imperfect between
these restriction sites and the L versus S groupings, such
that some ethnic groups exhibit a very tight linkage (thus
displaying a clear correlation between BMD and the BsmI
site), while in others (e.g., African-Americans) the presence
of the BsmI or TaqI site is not a good predictor of the L
versus S genotype,(92) leading to a loss of functional corre-
lation between BsmI or TaqI and BMD. Nonetheless, the
study of the poly(A) microsatellite sequence may have
brought us closer to a functional understanding of VDR
genetic diversity, while also providing a partial explanation
for the variability in association of BsmI or TaqI genotypes
with BMD and hyperproliferative disorders.
Near the 59 end of the hVDR gene, a FokI restriction
endonuclease site has been identified,(96,97) the presence of
which (denoted f) dictates that the 427-residue, M1 isoform
of VDR is expressed (so named because it contains an ATG
methionine translational start site corresponding to codon
#1). An evolutionarily more recent polymorphism
(Fig. 3),(98) or neomorph, has been reported in which both
the FokI restriction site and the ATG codon #1 are
changed, causing an alternative 424-residue isoform of the
receptor to be translated. The F neomorph, encoding M4
hVDR (for initiation of translation at the fourth codon)
already constitutes approximately 65% of VDR alleles in
human subjects (L. Remus and M. Haussler, unpublished
results), intimating an evolutionary advantage in humans.
The FokI polymorphism, which is not linked to the afore-
mentioned cluster of variations in the 39 region of the gene,
may therefore have significance for human bone pathology.
Indeed, the M4 isoform is more transcriptionally active
VITAMIN D RECEPTOR 331
than the M1 VDR in a transient transfection assay employ-
ing a VDRE-linked reporter gene.(96) We have indepen-
dently observed that the M4 hVDR is significantly more
effective than the longer M1 receptor in activating the
transcription of VDRE–reporter constructs in several trans-
fected mammalian cell lines, including osteoblasts (L. Re-
mus and P. Jurutka, unpublished results). The conclusion
that the M4 (F) hVDR isoform is more transcriptionally
potent is in concert with recent studies which suggest an
association between the F hVDR allele and enhanced BMD
in two different populations.(96,97) This raises the possibility
that the F neomorphic VDR allele, and speculatively the L
grouping of microsatellite variants (linked to varying de-
grees with b/a/T alleles), may provide partial protection
against osteoporosis by ensuring enhanced BMD via the
increased activity of hVDR throughout life.
Functional domains in the VDR protein
As depicted schematically in Fig. 2(B) and conceptual-
ized later in this review, VDR is a 1,25(OH)2D3-dependent
transcription factor that controls gene expression by het-
erodimerizing with retinoid X receptors (RXRs) and asso-
ciating specifically with VDREs in target genes.(99) The
principal functional domains of hVDR (Fig. 2B) that effect
this action include those for hormonal ligand binding, het-
erodimerization, DNA binding/nuclear localization, and
transcriptional activation. The lower portion of Fig. 2(B)
also illustrates the 18 point mutations in VDR detected to
date in HVDRR patients (reviewed in Refs. 10–13 and
100). Five of these genetic alterations result in nonsense
(X) or frameshift (f) mutations that introduce premature
stop codons in the receptor (R73X, E92f,(101) Q152X,
L233f, and Y295X), creating truncated VDRs that lack
both hormone- and DNA-binding/heterodimerization ca-
pacities and are associated with unstable mRNAs. More
revealing are the series of missense mutations (Fig. 2B) that
can be classified according to three of the major molecular
functions of VDR: DNA binding/nuclear localization by the
N-terminal zinc finger region (G33D through R80Q), 1,25-
(OH)2D3 hormone binding by the C-terminal domain
(R274L, H305Q, and I314S), and heterodimerization with
RXRs through subregions of the C-terminal domain (I314S
and R391C).
DNA binding
As with other nuclear receptors, all VDRs described to
date possess a conserved DNA binding domain consisting
of two zinc finger motifs (Fig. 2B and Fig. 3, residues 24–90
in hVDR). Although X-ray crystallographic data are not yet
available for VDR, the solution of the cocrystal structure
for the DNA binding domains of thyroid hormone receptor
(TR)-RXR on a thyroid hormone responsive element
(TRE)(102) provides an initial approximation of VDR struc-
ture/function in the DNA binding region. Accordingly, as
detailed in Fig. 3, an a-helix resides on the C-terminal side
of each zinc finger, with helix A and helix B constituting the
DNA-recognition and phosphate backbone binding helices,
respectively. Among the naturally occurring missense mu-
tations in this segment of hVDR (Fig. 2B), his-35, lys-45,
arg-50, arg-73, and arg-80 all correspond to DNA contacts
in the TR-RXR–TRE cocrystal. That these alterations
cause the HVDRR phenotype of 1,25(OH)2D3 resistance in
patients(10) argues strongly for the existence of a reasonable
structural congruity between the VDR finger region and
that of TR.
As a further analogy with the TR–RXR cocrystal,(102) the
FIG. 3. Amino acid comparison among four of the six
VDRs cloned to date. Shown are sequences from human
(Hu),(147) mouse (Mus musculus, abbreviated Ms),(149)
chicken (Gallus gallus, denoted Ch),(1,150,151) and Xenopus
laevis (Xl).(18) Numbering is for the hVDR as published by
Baker et al.(147) Not shown are sequences from rat(148) and
Japanese quail,(151) which are similar to the mouse and
chicken, respectively. Alternative translation start sites for
chicken (Ch) or human (Hu) mRNAs are indicated by
arrows. The approximate location of residues correspond-
ing to a-helices (h-A, h-1, etc.) in the crystal structures of
hTRb,(102) rTRa(119) and hRARg(118) are indicated by
brackets above the sequences. By similar analogy, ligand
contacts in rTRa(119) and hRARg(118) are indicated by solid
triangles below the sequences if found in both crystal struc-
tures, or by open triangles if found in only one structure.
Artificial point mutations in hVDR that inhibit transcrip-
tional activity without affecting either 1,25(OH)2D3 binding
or heterodimerization are denoted by solid circles under the
sequences. An asterisk indicates the stop codon.
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region just C-terminal to the zinc fingers in VDR (Fig. 2B,
residues 91–115 in hVDR), containing the T- and A-box
helical region (denoted helices C/D in Fig. 3), likely also
provides DNA contacts. The functional significance of pu-
tative helices A–D in DNA binding by VDR is emphasized
by the near absolute conservation across species of the
residues therein (Fig. 3). An interesting point concerning
the VDR DNA binding domain is the presence, unique to
VDRs, of a cluster of five basic amino acids in the inter-
vening sequence between the two zinc fingers (Fig. 2B, Q;
residues 49–55 in Fig. 3). Four of these positively charged
residues (excluding lys-55) are hypothesized to make DNA
contact based on the Rastinejad model,(102) but this region
is also crucial for nuclear localization of the receptor.(103) In
addition, this segment includes ser-51, a site of hVDR
phosphorylation (Fig. 2B) by protein kinase C(104) that
results in inhibition of VDRE binding by phospho-VDR, in
vitro.(105) Thus, phosphorylation of ser-51 could conceiv-
ably modulate both DNA-binding and nuclear localization
of VDR, in vivo.
Nuclear localization
Biochemical fractionation and in situ immunocyto-
chemical localization studies have shown that VDR is
predominantly a nuclear protein, even in the unoccupied
state.(106 –110) Two studies to date have examined poten-
tial nuclear localization domains in hVDR,(103,111) focus-
ing mainly on stretches of basic amino acids, such as those that
have been implicated in nuclear localization of other steroid
hormone receptors.(112–114) The results of Luo et al.(111)
suggest that a bipartite signal consisting of a cluster of basic
residues at each end of the sequence between amino acids
79 and 105 of hVDR is required for nuclear accumulation.
Hsieh et al.(103) have identified a separate basic sequence
between the two zinc fingers of hVDR (residues 49–55)
that represents a second nuclear localization signal. It re-
mains unclear whether the identified three basic clusters of
positively charged residues, which are absolutely conserved
in helices A, B, and C (Fig. 3), function together or inde-
pendently to effect nuclear translocation. The observations
that point mutations causing HVDRR occur at arg-80(115)
in the bipartite signal, and at arg-50(116) in the second
signal, and that neither mutated receptor is competent in
transferring ligand to the nucleus, strongly suggest a neces-
sity for both nuclear localization signals. Finally, as denoted
in Fig. 2(B), the entire DNA binding domain, as a func-
tional unit, may be required for optimal retention of VDR
in the nucleus as a result of the general interaction of VDR
with DNA.(115,117)
Hormonal ligand binding
Based upon the partial X-ray crystal structures of human
retinoic acid receptor g (hRARg),(118) rat TRa1,
(119) as well
as unoccupied but homodimeric hRXRa,(120) the ligand
binding domain of nuclear receptors consists of a “sand-
wich” of 12 a-helices and several short b-strands organized
in three dimensions around a lipophilic hormone-binding
pocket. Following this analogy, three regions of hVDR in
closest proximity to the 1,25(OH)2D3 ligand would extend
approximately from residues 227–240, 268–316, and 396–
422 (Fig. 2B). As shown in Fig. 3, ligand contact sites at the
individual amino acid level in the crystal structures of li-
gand-occupied hRARg(118) and agonist-occupied rTRa1
(119)
map to clusters in helix 3, helix 5, helix 11, and helix 12, as
well as the b-strands (not delineated) that flank helix 6.
Several of the mutations characterized in hVDR that com-
promise ligand binding coincide with hormone contact sites
in RAR and/or TR. These include the natural mutations
R274L(121) and H305Q,(13) as well as artificial hVDR mu-
tations at leu-233,(122) cys-288,(123) and his-397.(124) The
conclusion from these identified mutant hVDRs is that the
structure of the VDR ligand binding domain, with the
exception of relatively unconserved amino acids between
residues 155 and 194 (exon V, see above and Fig. 3), closely
resembles that of its nuclear receptor subfamily cousins,
RAR and TR. A similar thesis has been presented inde-
pendently by Wurtz et al.,(125) who modeled the hormone
binding domain of liganded VDR utilizing coordinates
from the X-ray crystal structure of holo-RARg.
Heterodimerization with RXR
From large deletion studies with VDR, Nishikawa and
coworkers(126) determined that VDR dimerization surfaces
are found in the first zinc finger, in a region just C-terminal
of finger-2, and in the large C-terminal ligand binding
domain. Higher resolution mapping experiments have re-
vealed that weak heterodimerization between VDR and
RXR is facilitated by specific contact sites in the DNA
binding domain of VDR (Fig. 2B). By site-directed mu-
tagenesis, Hsieh et al.(127) have shown that lys-91 and glu-
92, which are situated in the T-box region of hVDR (just
C-terminal of finger-2 at the beginning of helix C in Fig. 3),
mediate heterodimerization between the VDR and RXR
DNA binding domains on the VDRE scaffold. This finding
is independently supported by a modeling study,(102) which
also identifies Asn-37, located in the first zinc finger of
hVDR, as an amino acid that contacts residues in the
second zinc finger of the RXR partner in determining
selective association of VDR with a VDRE consisting of a
direct repeat spaced by three nucleotides (DR3). Within
the hormone binding domain, two regions of hVDR that
are involved in strong, ligand-dependent heterodimeriza-
tion with RXR have been deduced by mutagenesis experi-
ments and by analogy to the RXR homodimer crystal
(Fig. 2B).(120) These two subdomains consist of hVDR resi-
dues 244–263,(100,128–130) and amino acids 317–395,(124,130)
corresponding to portions of helices 3–4 and 7–10, respec-
tively (Fig. 3). The helix 7–10 region is positionally equiva-
lent to contacts between hRXRa residues in a homodimer
as determined via X-ray crystallography by Bourguet et
al.(120) Thus, as illustrated in Figs. 2 and 3, the schematic
picture of hVDR that is developing not only maintains the
modular concept of receptor organization with general
DNA and hormone binding domains, but also illuminates
the complexity of regions within the ligand binding domain
required for supporting both heterodimerization and hor-
mone binding functions. The aforementioned I314S and
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R391C natural mutations (Fig. 2B) are unique because they
provide evidence for a potential structural interplay be-
tween heterodimerization and hormone binding of VDR.
I314S, which endows hVDR with combined defects in both
hormone retention and heterodimerization,(11) lies within
helix-7, near a presumed juncture of ligand binding and
heterodimerization subdomains of the receptor (Fig. 2B).
Likewise, R391C is positioned within the helix-10 dimeriza-
tion surface, but not far removed from C-terminal ligand
binding contacts (Figs. 2B and 3), consistent with the ob-
served phenotype of a primary heterodimerization defect
and a milder, secondary ligand retention deficiency.(11) The
conclusion is that the ligand binding and heterodimeriza-
tion functions are interrelated within the context of the
tertiary structure of VDR, likely via allosteric effects that
ultimately generate an active receptor conformation.
Transactivation
The mechanism of transcriptional up-regulation em-
ployed by the agonist activated RXR–VDR heterodimer,
once bound to DNA, is just now becoming understood.
Functional evaluation of VDR points to at least two regions
of the receptor required exclusively for transcriptional ac-
tivation. One of these regions (residues 244–263) has al-
ready been noted for its role in heterodimerization (see
above). However, embedded in this domain is lys-246 in
hVDR (Fig. 3, denoted by a solid circle below the sequenc-
es), a residue not involved in heterodimerization, but whose
alteration, even by conservative arginine replacement, se-
verely compromises transactivation.(129) A recent report
has extended this observation to the estrogen receptor,(131)
and proposes, as did Whitfield et al.,(129) that this residue,
which is highly conserved among nuclear receptors, forms
part of the binding interface with transcriptional coactiva-
tors (see Fig. 4 and later discussion). The second region, by
analogy with other nuclear receptors, is known as a ligand-
dependent activation function or AF-2, and corresponds to
helix 12 (Fig. 3) of the hormone binding domain.(132–135)
Analysis of this domain in hVDR by site-directed mutagen-
esis has identified leu-417 and glu-420 (also denoted by
solid circles in Fig. 3) as pure, hormone-dependent tran-
scriptional activation residues, with their alteration having
little effect on either hormone binding or heterodimeric
DNA binding.(136,137) Like lys-246, leu-417 and especially
glu-420 function to stimulate transcription by a mechanism
involving coactivators.(136–138)
The transcriptional capacity of hVDR can be modulated
in response to phosphorylation by kinases that participate
in distinct signal transduction pathways.(139,140) For exam-
ple, hVDR is phosphorylated by protein kinase A (PKA),
presumably in the central portion of the molecule between
the DNA and hormone binding regions, resulting in an
attenuation of 1,25(OH)2D3-activated transcription.
(141,142)
In addition, hVDR is phosphorylated by casein kinase II
(CK-II), in vitro, at ser-208, the major hormone-regulated
phosphorylation site, in vivo (Fig. 2B).(143,144) Overexpres-
sion of CK-II in mammalian cells effects a potentiation of
1,25(OH)2D3-stimulated transcription,
(145) indicating that
the control of gene expression by 1,25(OH)2D3–VDR can
be fine-tuned via phosphorylation, probably allowing for
cross-talk between the VDR and other signal transduction
pathways, and perhaps even governing receptor activity at
different stages of the cell cycle or during cell differentia-
tion.(139,146)
Comparison of VDRs across species
To date, VDR cDNAs have been cloned from six species,
namely human,(147) rat,(148) mouse,(149) chicken,(1,150,151)
Japanese quail,(151) and frog (Xenopus laevis).(18) As illus-
trated in Fig. 3, a direct comparison of the deduced amino
acid sequences from four of these VDRs reveals significant
sequence similarity. One variation that emerges from this
comparison is that both avian VDRs (only the chicken
sequence is shown) have a 22-residue N-terminal extension
that possesses two alternative translational start sites which
are positionally 59 of those in other VDRs.(150,151) In con-
trast, a 39 met-4 is an alternative translational start site in
the f (M1) hVDR allele shown in Fig. 3. As detailed above
in the human polymorphism section, in an apparently evo-
lutionarily advantageous neomorph of hVDR (F or M4),
the met-1 codon is mutated to render alternative met-4 the
translational initiation site.
Major regions of hVDR display a striking degree of
sequence similarity (Fig. 3), with the highest degree of
conservation occurring in those domains of known func-
tional significance. Prominent examples evident in Fig. 3
include the DNA-binding/nuclear localization domain (he-
lices A–D), and the helix 3–12 ensemble that performs an
intricate combination of 1,25(OH)2D3 binding, RXR het-
erodimerization and transactivation as discussed above. En-
compassing most of the amino acids encoded in exon V,
there occurs a poorly conserved central region (approxi-
mately residues 159–201 in hVDR) between putative heli-
ces 1 and 3 of the hormone binding domain, which displays
47% identity between human and rat, 19% between human
and Xenopus, and only 16% between human and chicken
VDRs. Not surprisingly, this segment of VDR is also
unique when compared with other nuclear receptors, a fact
that prevents assignment of helix 2 in VDR based on struc-
tural data from TR, RAR, or RXR (Fig. 3). Nevertheless,
the homology data in Fig. 3 provide compelling support for
the current linear structure/function model of hVDR pic-
tured in Fig. 2(B).
MECHANISM WHEREBY THE VDR–RXR
HETERODIMER MEDIATES THE ACTION
OF 1,25(OH)2D3 TO CONTROL
GENE TRANSCRIPTION
VDREs that mediate transactivation
Sequence and promoter analyses of several 1,25-
(OH)2D3-regulated genes have led to the identification of
VDREs, short DNA sequences to which the VDR binds as
a heterodimer with RXR and subsequently exerts its influ-
ence on transcription. The top portion of Table 2 lists those
VDREs identified in genes that are known to be transcrip-
tionally activated by the 1,25(OH)2D3 hormone, including
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osteocalcin and osteopontin (expressed in bone osteo-
blasts), b3 integrin (found in bone osteoclasts and macro-
phages), 24-OHase and NPT2 (discussed above), calbindin-
D28k (from kidney) and p21 (an inhibitor of cyclin-
dependent kinase [Cdk] in many tissues). In addition, two
laboratories(152,153) have probed VDRE criteria by random
selection of oligonucleotides that form complexes with
VDR in combination with RXR (Table 2, center), provid-
ing results that are in general agreement with the natural
VDREs. For positive transcriptional regulation, the VDRE
is thus defined as a DR3, or direct repeat of two 6-base pair
(bp) half elements that resemble estrogen-responsive ele-
ment half-sites, separated by a spacer of three nucleotides.
As depicted in Table 2 (top), VDR occupies the 39 half-site
of positive DR3 VDREs, while the 59 half-site is bound by
the RXR heteropartner.(154) Examination of both the nat-
ural and randomly selected VDRE sequences suggests that
the G at position 3 of the spacer is important in VDR
binding, a deduction consistent with the finding(155) that in
the rat osteocalcin motif this base is partially protected by
RXR–VDR in methylation interference assays. With the
exceptions of osteopontin and p21, numerous sequence
variations are evident in the 39 half-element of natural
VDREs when they are compared with the PuGTTCA ran-
dom consensus selection for this half-element (Table 2).
This variability could be related to a need for VDREs of
graded potency in regulated genes, or may even provide for
a repertoire of different VDR conformations that could be
induced by contact with distinct 39 half-site core sequenc-
es.(156) This postulated range of VDR conformations might
endow the receptor with the ability to recruit a variety of
different coactivators. Finally, the presence of two VDREs
in the 24-OHase gene promoter (Table 2) intimates that the
regulation of this enzyme is even more complex and may
manifest hypersensitivity in order to effect the rapid elimi-
nation of the 1,25(OH)2D3 hormone. Irrespective of the
above considerations, it is evident that the primary positive
VDRE is a DR3 recognition site in DNA that attracts
RXR–VDR to the promoter region of 1,25(OH)2D3-regu-
lated genes, ultimately adjusting the functions of target cells
as a result of transcriptional control of gene expression.
VDREs that mediate transrepression
Certain genes are negatively controlled at the level of
transcription by the 1,25(OH)2D3 hormone, and this trans-
repression apparently occurs by several different mecha-
nisms, including primary or secondary effects. For example,
secondary effects involving the induction of intermediary
proteins include 1,25(OH)2D3 suppression of c-myc expres-
sion (Table 1),(157,158) and probably of atrial natriuretic
peptide in cardiac myocytes (Table 1 and S. Chen et al.,
unpublished results). In what may be a primary effect, Alroy
et al.(159) report that VDR binds, in vitro, to the human
TABLE 2. VDRE SEQUENCES IN VDR-REGULATED GENES
Gene
Effect on
transcription* Vitamin D responsive element† Reference(s)
5*-RXR 3*-VDR
Rat osteocalcin 1 GGGTGA ATG AGGACA (155, 233–235)
Human osteocalcin 1 GGGTGA ACG GGGGCA (236–238)
Mouse osteopontin 1 GGTTCA CGA GGTTCA (239)
Avian b3 integrin 1 GAGGCA GAA GGGAGA (240)
Rat 24-OHase-proximal 1 AGGTGA GTG AGGGCG (33, 241)
Rat 24-OHase-distal 1 GGTTCA GCG GGTGCG (242)
Mouse calbindin-D28k 1 GGGGGA TGT GAGGAG (243)
NPT2 1 GGGGCA GCA AGGGCA (41)
p21 (Cdk inhibitor) 1 AGGGAG ATT GGTTCA (228)
Random selection‡ 1 PuGGTCA NNG PuGTTCA (152, 153)
VDR (RXR?) RXR (VDR?)
Avian PTH 2 GGGTCA GGA GGGTGT (244)
Human PTH§ 2 GGTTCA AAG CAGACA (29, 39)
Mouse osteocalcin 2 GGGCAA ATG AGGACA (162)
Rat bone sialoproteini 2 AGGGTT TAT AGGTCA (245)
PKA inhibitor 2 ATGTTG CTG AGGTCA (165)
Rat PTHrP-proximal 2 AGGTTA CTC AGTGAA (246)
Rat PTHrP-distal 2 GGGTGG AGA GGGGTG (247)
*VDREs activated by 1,25(OH)2D3–VDR are shown in the upper portion and those repressed are listed in the lower portion.
†Bases depicted in darker type are those homologous to the randomly selected, highest affinity VDRE.
‡Consensus VDRE determined by binding of VDR–RXR heterodimers to randomly synthesized oligonucleotide sequences;
Pu 5 purine.
§VDR heterodimerizes with a factor distinct from RXR on this VDRE.
iAntisense TATA box is underlined.
VITAMIN D RECEPTOR 335
IL-2 promoter to prevent NFATp/AP-1 complexing with
the DNA, thereby effecting transrepression. However, un-
like the rat osteocalcin gene, where liganded VDR has been
shown to associate with the positive VDRE via in vivo
footprinting,(160) no evidence has been provided that VDR
directly binds to the IL-2 promoter in a ligand-dependent
fashion, in vivo.
In other cases of transrepression by 1,25(OH)2D3, there
also exist data that VDR binds to the promoter in question,
in vitro, and does so in a heterocomplex with RXR, or with
another tissue-specific silencing coreceptor. For instance,
VDR represses human PTH transcription in a 1,25-
(OH)2D3-dependent manner by complexing with a corecep-
tor distinct from RXR,(29) but on an element that resembles
a degenerate DR3 VDRE with substitutions in the 39 half-
element (Table 2, lower portion). The putative avian PTH
negative VDRE is also similar to the consensus positive
VDRE, except that the G in the spacer and the last two
bases (CA) in the 39-half element are replaced by other
nucleotides (Table 2). Interestingly, when Russell and co-
workers(161) altered the two 39 terminal bases (GT) back to
the consensus CA, the avian PTH VDRE reverted from a
negative to a positive VDRE. Moreover, the mouse osteo-
calcin VDRE, which unlike the rat and human osteocalcin
VDREs confers negative control by 1,25(OH)2D3,
(162) also
possesses only two base differences (positions 4 and 5 of the
59 half-element) from that of the rat sequence (Table 2). A
separate secondary mechanism for negative osteocalcin
control by 1,25(OH)2D3 in the mouse appears to involve
suppression of an osteoblast-specific activator that binds to
a cis-acting element in the promoter.(163) Nevertheless,
based upon observations with VDREs in the avian PTH
gene as well as mouse versus rat osteocalcin, simply chang-
ing 2 bp in either half-element of a VDRE reverses the
direction of transcriptional regulation by 1,25(OH)2D3 as
mediated by the VDR. How is this on–off switch accom-
plished mechanistically? One possibility is that the polarity
of the RXR–VDR heterocomplex on the VDRE is altered
such that the VDR occupies the 59 half-element when gene
control is negative.(161) There is, in fact, precedent for
binding orientation reversal conferring negative regulation
in the case of the RAR–RXR heterocomplexes.(164) An-
other possibility is that base pair substitutions in either
half-element conform the VDR complex such that it cannot
recruit a coactivator, or perhaps retains a corepressor. The
concept of VDRE association altering the tertiary structure
of VDR is supported by the observation that a 2 bp change
of TT to GA in positions 3 and 4 of the 39 half-element, as
in the mouse osteopontin versus rat osteocalcin VDREs,
appears to alter the conformation of VDR as judged by
antibody epitope accessibility and protease sensitivity.(156)
Either or both of the potential mechanisms of reverse
VDR/RXR orientation or negative VDR conformation
could come into play in primary transrepression. Yet a third
mechanism involving occlusion of an active site in the pro-
moter apparently occurs with the bone sialoprotein gene
upstream region, wherein the RXR–VDR or VDR–RXR
complex binds to a VDRE overlapping an inverted TATA
box (Table 2), presumably occluding TATA-binding protein
association. A similar situation may occur in the case of the
PKA inhibitor gene (Table 2), in which a putative negative
VDRE is situated between two TATA sequences.(165) How-
ever, more research is clearly needed before we will have a
comprehensive understanding of negative transcriptional
regulation by VDR.
The effect of 9-cis retinoic acid, the ligand for RXR,
on VDR signaling
An additional level of control of the VDR-RXR het-
erodimer could conceivably be exerted by RXR ligands,
primarily the natural 9-cis retinoic acid (9-cis RA) hor-
mone.(99) Precedents from other receptors that het-
erodimerize with RXR encompass a spectrum of effects.
With respect to transactivation by all-trans RA as mediated
by the RXR–RAR heterodimer, subsequent addition of
RXR-specific ligands, referred to as rexinoids, further aug-
TABLE 3. EFFECTS OF 9-CIS RETINOIC ACID LIGAND FOR RXR ON TRANSACTIVATION BY THE VDR–RXR HETERODIMER
Antagonistic effects*
1. Blocking of 1,25(OH)2D3 antiproliferative action on HT-29 colon cancer cells;
(170) inhibition of 1,25(OH)2D3
stimulated chondrogenesis of chick limb bud mesenchymal cells(248)
2. Inhibition of 1,25(OH)2D3-induced osteocalcin mRNA accumulation in ROS 17/2.8 osteosarcoma cells
(99)
3. Inhibition of 1,25(OH)2D3-mediated VDR-RXR binding to osteocalcin and osteopontin VDREs
(99,249,250)
4. Suppression of 1,25(OH)2D3-elicited transactivation of a reporter gene from an osteocalcin or osteopontin-like
VDRE in transfected cells(99,175)
Additive or synergistic effects*
1. Antiproliferative actions on the following cells in culture: human pancreatic carcinoma (Capan-1 and
Capan-2),(169) colon cancer (Caco-2),(170) human promyelocytic leukemia (U937 and HL-60),(231,251–253) prostate
cancer (LNCaP),(173) and breast cancer (MCF-7)(254)
2. Induction of 24-OHase mRNA in human skin(171) and colon cancer cells (HT-29)(170)
3. None reported
4. Transactivation in transient transfections employing the following VDREs: synthetic perfect DR3s consisting of
GGGTGA(174) and AGGTCA(174,255) half elements, both rat 24-OHase VDREs,(256) mouse osteopontin
VDRE,(174) human osteocalcin VDRE,(174) and a putative inverted repeat VDRE in the calbindin-D9k gene
(257)
*1. Cell growth and differentiation; 2. mRNA accumulation; 3. VDR-RXR heterodimerization; 4. transactivation.
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ments gene activation from a retinoic acid response ele-
ment.(166–168) Conversely, the occupation of TR by thyroid
hormone in an RXR–TR heterodimer silences the ability of
that complex to bind and respond to 9-cis RA in terms of
transactivation of a TRE-reporter construct.(166) Studies
with VDR have variously indicated antagonistic, additive,
or synergistic effects of 9-cis RA in combination with
1,25(OH)2D3 (Table 3). In an attempt to reconcile these
conflicting data, it is important to realize that these studies
tend to assess four distinct endpoints: growth and differen-
tiation of intact cells, accumulation of specific mRNAs, gel
mobility shift assays of the heterocomplex binding to a
VDRE, and transactivation from VDRE–reporter con-
structs in cotransfected cells. When the current body of data
is considered, in toto, only the antagonistic effect of 9-cis
RA on 1,25(OH)2D3 action is demonstrable at all four of
the above levels (Table 3). Rat osteocalcin control is a
prominent example in which 9-cis RA attenuates the ability
of 1,25(OH)2D3 to elicit mRNA accumulation, het-
erodimeric VDRE binding, and transcription from a
VDRE–reporter construct. Antagonism by 9-cis RA in the
rat osteocalcin system may involve a simple RXR diversion-
ary mechanism under conditions of high local levels of 9-cis
RA and limiting RXR concentrations (see Fig. 4 below).
Positive effects of 9-cis RA on the action of 1,25(OH)2D3
appear to be a more complex, though seemingly widespread
phenomenon (Table 3), perhaps occurring at multiple steps
in cell and gene regulation. For example, as listed in
Table 3, the combination of 9-cis RA and 1,25(OH)2D3
exerts additive growth inhibitory effects in select whole cell
systems such as human pancreatic carcinoma (Capan)
cells(169) and colon carcinoma (Caco-2) cells.(170) Synergis-
tic actions of 1,25(OH)2D3 and 9-cis RA have been noted
mainly in cell growth and differentiation systems, in which a
marked antiproliferative effect occurs in the presence of
both ligands (Table 3). In addition, 24-OHase mRNA is
synergistically enhanced in its accumulation when both li-
gands are present in two different cell systems.(170,171) How-
ever, in no case has 9-cis RA been shown to increase
(directly) 1,25(OH)2D3-mediated binding of VDR–RXR
heterodimers to VDREs (Table 3). Furthermore, there is
no definitive proof in many of these systems that the posi-
tive effect of 9-cis RA involves exclusively RXR–VDR het-
erodimeric action on VDREs. For instance, 9-cis RA binds
to RAR as well as RXR, raising the possibility that actions
of this pan-ligand for retinoid receptors could transpire via
the RXR–RAR heterodimer, although two of the relevant
investigations(172,173) demonstrating synergism utilized
RXR-specific (rexinoid) ligands, obviating any binding to
RAR.
Synergistic activation of transcription linked to selected
natural and synthetic VDREs also has been reported when
transfected cells are exposed to both 9-cis RA and 1,25-
(OH)2D3 (Table 3), including results with the osteopontin
VDRE(174) that conflict with those of Lemon and Freed-
man(175) who reported antagonism (Table 3). Caveats to
these VDRE experiments are that the transient transfection
studies often involved synthetic VDREs lacking natural
flanking regions, overexpression of both partner receptors
well beyond physiologic concentrations, or the use of het-
erologous cell systems. In genes whose 1,25(OH)2D3-in-
duced expression is truly amplified by 9-cis RA and RXR-
specific ligands, conceivable mechanisms could involve
unique VDRE or flanking cis-element effects on the con-
formation of the RXR partner in the heterodimer such that
it is receptive to the binding of rexinoids as agonists (see
Fig. 4 and the next section).
The dual 24-OHase VDREs (Table 2) are again of par-
ticular interest in that, in contrast to the single rat osteo-
calcin VDRE, this VDRE pair confers synergistic activation
by 9-cis RA and 1,25(OH)2D3, both from a reporter con-
struct and in the setting of the endogenous gene (Table 3).
Other results(176) indicate that 9-cis RA alone can positively
influence 24-OHase gene transcription, rendering the RXR
ligand a regulator of vitamin D metabolite catabolism.
Therefore, 9-cis RA could achieve an effective biological
suppression of bone remodeling by blunting the positive
action of 1,25(OH)2D3 on osteocalcin transcription and by
independently inducing the 24-OHase enzyme that in turn
initiates the destruction of the 1,25(OH)2D3 hormone
(Table 3). Future research will be needed to clarify the
mechanisms by which 9-cis RA influences 1,25(OH)2D3–
VDR signaling, and also to explain the largely unknown
effects of 9-cis RA on VDR–RXR heterodimers that bind
to negative VDREs.
TABLE 4. INTERACTION OF VDRES WITH NEARBY OR OVERLAPPING CIS ELEMENTS THAT BIND REGULATORY PROTEINS
Gene VDRE-type Cis-trans modifier
Effect on
transcription Reference
Rat osteocalcin DR3 Inhibitory YY1 competes with VDR/RXR
by overlapping the VDRE
2 (177)
Human osteocalcin DR3 Upstream AP-1/fos-jun 1 (238)
Rat osteocalcin DR3 Downstream ligand-dependent
transcription sequence (GGTTTGG)
1 (258)




(AP-2-like) adjacent to proximal DR3
1 (259)
Mouse c-fos composite CAAT-binding transcription factor binds
along with VDR and RXR
1 (179)
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Role of DNA sequences flanking or overlapping
VDREs in positive VDR signaling
Beyond the various agonist/antagonist effects of the two
receptor ligands and sequence variation within the DR3
VDRE, additional regulatory influences could be exerted
by other cis-elements within the promoter region that bind
generic or tissue-specific transmodulators. The simplest
mechanism for such cis-elements to affect VDR-mediated
transcription is to overlap the VDRE, analogous in theory
to the bone sialoprotein negative VDRE (discussed above)
that possesses an intrinsic TATA box sequence. In fact,
such overlap occurs when the trans-repressor YY1(177)
binds to the rat osteocalcin VDRE region during the early
stages of osteoblast differentiation to prevent VDR action
(Table 4). More commonly, adjacent cis-elements and their
associated transfactors appear to positively modulate tran-
scriptional activation by the VDR–RXR heterocom-
plex.(178) Specifically, 1,25(OH)2D3-stimulated transcrip-
tion from human and rat osteocalcin promoters is further
augmented by the involvement of an upstream AP1, or a
downstream GGTTTGG sequence, respectively (Table 4).
Also, calbindin-D28k, which is only modestly activated by
1,25(OH)2D3 at the transcriptional level, possesses an ad-
jacent butyrate responsive element (Table 4) that supple-
ments the effect of the hormone. A more complex situation
exists in the aforementioned case of 24-OHase transcrip-
tion, where the two VDREs (Table 2), approximately 100
bp apart in the promoter, plus the cooperation of the
proximal VDRE with an adjacent AP-2-like sequence, are
all required for full transcriptional activation (Table 4).
Another mechanism discovered for cis-trans modification of
a VDR–RXR bioeffect is the transient expression of the
c-fos gene.(179) This gene contains a composite VDRE dis-
tinct from a simple DR3, on which a bone cell-specific
member of the CTF/NF-1 family of CAAT-box binding
proteins forms an activating trimeric complex with VDR
and RXR (Table 4). The examples discussed above indicate
that there is potential for other signal transduction path-
ways to impinge on VDR function, and such cross-talk
could be relevant in terms of the tissue and promoter
selectivity of 1,25(OH)2D3 action. As target gene parame-
ters are more carefully dissected, additional examples of
such regulatory complexity will likely emerge.
Integration of VDR interacting proteins into a model
for transcriptional control by 1,25(OH)2D3
To function as a ligand-dependent transcription factor,
VDR must interact with a number of regulatory and signal
transducing proteins (Table 5). The binding of VDR to
DNA may be negatively controlled through association with
calreticulin, a calcium-binding macromolecule capable of
sequestering members of the nuclear receptor superfamily
by contacting and masking the DNA recognition helix
within the zinc finger region.(180) It has been proposed that
calreticulin association with VDR might somehow coordi-
nate 1,25(OH)2D3 action with the calcium status of the cell
(reviewed in Ref. 180). In addition to calreticulin, another
putative calcium binding protein that interacts with VDR is
ERC-55 (Table 5), although a functional role for this pro-
tein–protein contact has not yet been defined.
Unliganded VDR in the nucleus is likely bound to a
corepressor related to the silencing mediator for retinoid
and thyroid hormone receptors (SMRT) (Table 5 and
Fig. 4).(181) It is proposed that, analogous to closely related
receptors such as RAR,(182) the VDR–SMRT/corepressor
complex is linked to histone deacetylase(s) that maintains
chromatin in a repressed state with respect to transcription.
As shown in Fig. 4, unliganded VDR is also envisioned to
be weakly heterodimerized with RXR, and this multimer is
postulated to be loosely and nonspecifically associated with
DNA, perhaps sliding along the nucleic acid phosphate
backbone. Upon VDR occupation by 1,25(OH)2D3, the
receptor undergoes a dramatic conformational change, re-
sulting in the following events which are illustrated in Fig. 4:
dissociation of the corepressor; repositioning of the VDR
AF-2 to the stimulatory, closed configuration; stabilization
of the active conformation of VDR by phosphorylation;
TABLE 5. CANDIDATE VDR-INTERACTING-PROTEINS (VIPS)
VIP
Ligand
dependency Proposed function of protein or complex Reference(s)
Calreticulin 2 inhibitor of DNA binding (260, 261)
ERC-55 2 calcium binding protein (262)
SMRT 1 corepressor (263)
RXR 1 active partner in DNA binding and transactivation (99, 264)
SRC-1 (ACTR, TIF2,
GRIP1, ERAP160)*
1 coactivator, histone acetylation (137, 265, 266)
NCoA-62 2 coactivator (267)
p65 1 coactivator (268)
TIF1 1 chromatin remodeling (269)
TAFII28 1 TBP-associated factor (270)
TFIIB 6 basal transcription factor (177, 264, 271, 272)
SUG1 1 receptor degradation (186, 187)
*Synonyms are listed in parenthesis
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high affinity heterodimerization with RXR (Table 5), with a
concomitant allosteric effect to configure the AF-2 of RXR
into an active conformation; and specific recognition and
tight association with the VDRE. As discussed earlier in
this review, DR3 VDREs can be either positive or negative
in their influence on gene transcription (Table 2). In the
simplest mechanism (Fig. 4), positive VDREs like that in
the mouse osteopontin gene bind the heterodimer with
VDR situated on the 39 half-element. Conversely, negative
VDREs such as in the avian PTH gene may be determined
by a reverse orientation of binding, with VDR residing on
the 59 half-element. However, as discussed above, a more
intricate mechanism for establishing positive or negative
regulation by 1,25(OH)2D3 could involve specific base pairs
in either VDRE half-element dictating various receptor
conformations that in turn are manifest as either transacti-
vation or transrepression. As already outlined in Tables 3
and 4, and depicted in Fig. 4, the cis-environment of the
FIG. 4. Working model for transcriptional control by 1,25(OH)2D3. (Bottom) Unliganded VDR binds weakly to RXR
and DNA and may also bind to a putative corepressor that promotes silencing of gene expression via recruiting histone
deacetylase activity. Histone deacetylase maintains histones such that they promote a repressive nucleosome configuration
in chromatin. Heavy solid arrows denote the proposed major pathway in which 1,25(OH)2D3 (v) enters the nucleus, binds
VDR, and leads to high affinity association of the active 1,25(OH)2D3–VDR–RXR complex with specific VDREs in the
promoter regions of target genes. (Center and top) Liganded hVDR is transformed into an active conformation, with the
AF-2 in the closed position (see legend at left), and also becomes phosphorylated on serine-208 in a 1,25(OH)2D3-
dependent reaction, which potentiates transactivation by VDR. There is a high affinity interaction of 1,25(OH)2D3-
occupied VDR with RXR, which is postulated to influence the structure of RXR by bringing its AF-2 into the active
orientation. In this model, positive VDRE binding by the activated heterodimer, with VDR positioned on the 39
half-element, leads to transcriptional derepression/stimulation of target genes via a combination of the following events:
attraction of VDR coactivators that mediate derepression of chromatin nucleosome organization via histone acetyl
transferase (HAT) catalyzed displacement of histones to unveil DNA, contact of VDR coactivators with TAF–TBP
complex on the TATA box, and direct association of VDR with elements of the basal transcription machinery, such as
TFIIB, to stabilize the preinitiation complex. Whether RXR also enlists coactivators that possess HAT activity and/or
contact the general transcription apparatus has not been demonstrated, although the AF-2 of RXR in the heteropartner
is absolutely required for transcriptional activation.(273) Conversely, as indicated with a heavy broken arrow, binding of the
VDR–RXR heterodimer to negative VDREs may place VDR on the 59 half-element, constituting one mechanism for
ligand-dependent repression of target genes by interfering with transcription in an undefined way, perhaps by VDR–RXR
existing in a conformation retaining corepressors or incapable of recruiting coactivators. (Top right) Polymorphic (F versus
f) forms of VDR are shown to modify transcriptional activity, in vivo, as a result of differences in VDR potency (within
the multimeric complex) between the short (M4) and long (M1) proteins encoded by these alleles. (Lower left) Modulation
by 9-cis RA of 1,25(OH)2D3-stimulated transactivation apparently occurs by either of two pathways. Antagonism ensues
when RXR is diverted away as a liganded homodimer to its own target, RXRE-containing genes, in the presence of high
local concentrations of 9-cis retinoic acid (). Alternatively, binding of 9-cis RA to the 1,25(OH)2D3-occupied, DNA-
bound heterodimer may be directed by distinct VDREs and/or modulatory cis-elements, resulting in an additive or
synergistic effect of these two ligands on transcription.
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VDRE and associated transmodulators may be able to
control both the 9-cis RA/rexinoid receptivity and magni-
tude of the 1,25(OH)2D3 response, perhaps also governing
promoter and cell selectivity, as well as allowing for cross-
talk with other signal transduction pathways.
An exciting development in the action of nuclear recep-
tors has been the recent isolation of coactivators,(182,183)
most of which appear to interact with the AF-2 domain.
Coactivator interactions with VDR are currently being in-
vestigated, and an association has been demonstrated with
ligand-dependent coactivators such as SRC-1, as well as
with ligand-independent coactivators like NCoA-62
(Table 5 and references therein; note the synonyms for
SRC-1). Beyond performing a crucial bridging function to
the general transcription apparatus, coactivators are now
thought to enzymatically modify histones in the nucleo-
somes in order to liberate DNA for transcription. This step
is catalyzed by histone acetyl transferases (HATs), which
possess the newly recognized feature of facilitating tran-
scriptional activation.(184) SRC-1 apparently possesses
HAT activity, but supplemental HAT proteins like CBP and
P/CAF,(182) as well as TIF1 (Table 5), also may be recruited
to a supercomplex (Fig. 4) that both derepresses the pro-
moter chromatin organization of the regulated target gene
and links to the general transcription apparatus. In the case
of the VDR–RXR heterocomplex, the primary receptor
also appears to attract basal transcription factors like
TAFII28 and TFIIB (Table 5). Therefore, we hypothesize
that by combining the bridging effects of coactivators and of
VDR, activation is targeted to the appropriate site of tran-
scriptional initiation, with subsequent recruiting of TFIIB
to trigger preinitiation complex assembly. In humans, this
action of VDR is seemingly more efficient with the M4 (F)
neomorphic variant than with the longer M1 (f) receptor
(Fig. 4, see VDR polymorphism section above), implying
that VDR alleles could be involved in the determination of
BMD.
Although little is known about the termination of the
1,25(OH)2D3–VDR signal beyond 24-OHase catalyzed ca-
tabolism of the ligand, interaction of activated VDR with
SUG1 (Table 5; not shown in Fig. 4 for simplicity) likely
targets the receptor for ubiquitination and subsequent pro-
teolysis by the 26S proteasome complex.(185–187)
The availability of a cell-free transcription system in
which VDR–RXR heterodimers activate transcription in a
1,25(OH)2D3-dependent fashion
(188) should facilitate stud-
ies of transcriptional control by VDR, such as demonstrat-
ing direct effects by coactivators, promoter-specific factors,
or corepressors. Ultimately, with such cell-free transcrip-
tion systems it may also be feasible to incorporate elements
of chromatin structure such as the aforementioned his-
tones, in order to develop a system that truly mimics VDR
action in vivo while at the same time permitting manipula-
tions, in vitro.
Recent mechanistically relevant observations on
1a,25(OH)2D3 analogs
Because of the magnitude of vitamin D analogs that have
been synthesized, comprehensive coverage in this review is
not feasible, and the reader is therefore referred to excel-
lent treatises on this topic(189,190) for a more detailed dis-
cussion. Nevertheless, the model in Fig. 4 suggests numer-
ous facets that may differ between particular target genes
and could therefore present opportunities for differential
manipulation of bioeffects via 1,25(OH)2D3 and/or 9-cis
RA analogs. Indeed, some success has already been re-
ported with this type of approach. Certain 1,25(OH)2D3
side-chain analogs, such as 20-epimerized derivatives, raise
calcium levels in the intact organism only slightly more than
the 1,25(OH)2D3 parent compound while at the same time
stimulating transcription of VDRE-reporter constructs
1000-fold more effectively,(191) whereas other analogs, such
as 22-oxa(192,193) or 16-ene(194) derivatives, exhibit sharply
reduced calcemic activity but retain the ability to inhibit
proliferation and induce cell differentiation. One analog in
the latter general class, calcipotriol, is already employed in
the treatment of psoriasis.(195) The advent of noncalcemic
derivatives allows for the desired antiproliferative or other
tissue-specific actions of 1,25(OH)2D3 without creating un-
wanted hypercalcemia as a toxic side-effect. A recent report
can serve as an example of what the future may hold. A
24-ethyl derivative of 1a(OH)D3, namely 1a(OH)D5, was
shown to be a potent, nontoxic inhibitor of the proliferation
of precancerous mammary lesions, in vivo,(196) suggesting
that 1,25(OH)2D3 derivatives may be used in cancer pre-
vention as well as treatment.
The exact mechanistic basis for the unique effects of
synthetic VDR ligands has not been elucidated, but there
are indications that specific analogs can differentially affect
ligand occupancy rates(191,197) or VDR conformational
states that may elicit distinct interactions with comodula-
tors.(198) For example, 20-epi analogs stabilize the recep-
tor,(197) presumably by binding deeper than 1,25(OH)2D3 in
the ligand pocket, thereby slowing ligand dissociation and
creating unique VDR (AF-2) conformational states that are
superactive transcriptionally.(198) Heterodimerization be-
tween VDR and RXR and resultant DNA binding is also
differentially influenced by 20-epi(191) and 16-ene(194) ana-
logs. Finally, utilizing the yeast two-hybrid assay, it has been
shown that ligand-enhanced VDR–RXR heterodimeriza-
tion correlates with transcriptional activation by a series of
1,25(OH)2D3 analogs.
(199) The current challenge is to elu-
cidate further the VDR-related events initiated by super-
active and bioselective 1,25(OH)2D3 analogs and to corre-
late these phenomena with pharmacologic profiles such
that their molecular mode of action is understood.
SUMMARY AND PROSPECTIVE
DEVELOPMENTS
The actions of 1,25(OH)2D3–VDR that have emerged
from recent studies include, but clearly transcend, the bone
and calcium/phosphate homeostasis effects originally attrib-
uted to vitamin D. This new understanding now encom-
passes many of the tissues formerly reported to contain
vitamin D receptors, but for which no function of the
vitamin-derived hormone could be ascribed. The insights
gained from VDR knockout and allelic variation research
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confirm and extend these concepts, raising the prospect
that, for the purpose of preventive measures, assessment
of VDR polymorphisms may ultimately become part of a
strategy to better identify and treat persons at risk for
common disorders such as osteoporosis, breast cancer, or
prostate cancer. We have learned much about VDR
structure/function from natural mutations in 1,25-
(OH)2D3-resistant patients and from site-directed mu-
tagenesis experiments, as well as gained insight from the
elucidation of analogous crystal structures for RAR,
RXR, and TR. The next few years will no doubt witness
a growing structural understanding of VDR, presumably
culminating in the crystallographic resolution of physical
details of liganded versus unliganded forms of VDR,
perhaps in the absence and presence of various protein
partners and/or VDRE binding sites. Such structural
information should allow for the design of the next gen-
eration of synthetic analogs possessing the potential ca-
pability of selectively controlling individual 1,25(OH)2D3
responses within the organism.
Fundamental investigations also have led to an en-
hanced appreciation of the sequence of events in nuclear
VDR signal transduction, offering promise that we may
be able to understand how diverse 1,25(OH)2D3 agonists
could differentially manipulate these steps in a promoter
and/or tissue-specific fashion. Such analogs would there-
fore be endowed with therapeutic potential not only for
classic VDR actions in calcium/phosphate homeostasis
and bone mineralization, but also for hyperproliferative
skin disorders and various types of cancer. A novel type
of analog that will be useful in studies of VDR action is
an authentic receptor antagonist, and preliminary re-
ports(200,201) indicate that this reagent may be available
soon. Another new frontier of VDR function at the
molecular level is clearly that of characterizing VDR-
interacting proteins, and identifying how they mediate
1,25(OH)2D3 signaling within the context of specific gene
promoters. These biochemical and genetic investigations
may reveal mechanisms for potential interactions of
1,25(OH)2D3 with signaling pathways for other hor-
mones, growth factors, and cytokines that physiologically
modulate the wide array of vitamin D bioeffects.
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